The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, local time. ELCC is a premier academic event in the field of lung cancer in Europe and globally. At this conference, multiple studies on the innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab, Hetronifly® in Europe), independently developed by Henlius, have been selected, comprehensively covering the therapeutic areas of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). These studies explored the clinical value of serplulimab in consolidative therapy for limited-stage small cell lung cancer (LS-SCLC) and neoadjuvant therapy for NSCLC, further supplementing real-world evidence for serplulimab in first-line treatment of squamous non-small cell lung cancer (sqNSCLC) and in combination with thoracic radiotherapy in extensive stage small cell lung cancer (ES-SCLC), continuously demonstrating and and solidifyingthe efficacy and potential of serplulimab in the treatment of lung cancer.
Lung cancer is one of the most common malignancies worldwide. According to GLOBOCAN 2022, there were over 2.48 million new cases of lung cancer globally in 2022, accounting for 12.4% of all new cancer cases 1. Lung cancer is classified into small SCLC and NSCLC, with SCLC accounting for approximately 15%2 of all lung cancer cases and is the most aggressive subtype of lung cancer. SCLC can be further divided into LS-SCLC and ES-SCLC. Serplulimab is the world's first anti-PD-1 mAb for first-line treatment of SCLC and the only anti-PD-1 mAb globally to succeed in a phase 3 registration clinical study for perioperative gastric cancer*. To date, serplulimab has been approved for the treatment of sqNSCLC, ES-SCLC, esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsqNSCLC). It has been approved for marketing in over 40 countries, including China, the United Kingdom, Germany, Singapore, Switzerland, and India, covering nearly half of the global population. With its differentiated mechanism, serplulimab has demonstrated unique advantages in the treatment of various solid tumors, achieving groundbreaking progress globally in the fields of lung cancer and gastric cancer. Its critical clinical study findings have been published in top academic journals such as JAMA, Nature Medicine, Cancer Cell, and the British Journal of Cancer, and it has received orphan drug designation in the United States, European Union, Switzerland, South Korea, and Mexico.
In lung cancer, serplulimab has covered the full range of first-line treatment. In addition to the approved indications for sqNSCLC, ES-SCLC, and nsqNSCLC, an international multicenter phase 3 clinical trial of serplulimab combined with chemoradiotherapy for first-line treatment of LS-SCLC has completed the subject enrollment. Bridging studies for ES-SCLC are being conducted simultaneously in the United States and Japan, and patient enrollment has been completed for the head-to-head bridging study for ES-SCLC in the United States.
The studies selected for ELCC 2026 are as follows:
SCLC
Title: Serplulimab Consolidation after Concurrent Hypofractionated Chemoradiotherapy for Limited-stage Small-cell Lung Cancer
Form: Poster
Number: 411P
Leading PI: Nan Bi, Jianchun Duan, Cancer Hospital, Chinese Academy of Medical Sciences
Time: 26 March 2026 13:00 - 14:00 (CEST)
Title: Clinical Efficacy of Consolidative Thoracic Radiotherapy Following Chemoimmunotherapy in ES-SCLC: A Real-World Comparative Study
Form: Poster
Number: 424P
Leading PI: Hualin Chen, Affiliated Hospital of Guangdong Medical University
Time: 26 March 2026 13:00 - 14:00 (CEST)
NSCLC
Title: A Prospective Study of Neoadjuvant Serplulimab Plus Chemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer (NSCLC)
Form: Poster
Number: 294P
Leading PI: Jian Zeng, Zhejiang Cancer Hospital
Time: 27 March 2026 13:00 - 14:00 (CEST)
Title: First-line Serplulimab for Advanced Squamous Non-small Cell Lung Cancer: Updated Survival of the ASTRUM-004R Trial
Form: Poster
Number: 88P
Leading PI: Bo Shen, Jiangsu Cancer Hospital
Time: 27 March 2026 13:00 - 14:00 (CEST)
References
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
2. Eskandar A, Ahmed A, Daughtey M, et al. Racial and sex differences in presentation and outcomes of small cell lung cancer in the United States: 1973 to 2010[J].Chest, 2015,147(4): e164-e165.